Want to buy Shire Plc? Get in line.
With drugmakers pursuing deals like never before, Shire Plc’s best defense against becoming a target may be to go on the hunt itself.
Valeant Pharmaceuticals International Inc.’s deal-fueled quest to become a $150 billion company has some investors doubting the strategy as it loads up on debt.
Drug deals are back and Mylan Inc. wants in.
Actavis Plc’s purchase of Forest Laboratories Inc. accelerates a pharmaceutical merger wave that stands to engulf even more drugmakers.
Impax Laboratories Inc. failed to win U.S. approval for a new version of an extended-release drug used to relieve spasms in patients with Parkinson’s disease.
Impax Laboratories Inc. declined the most in more than two months after the company failed to win U.S. approval for an extended-release formulation of a Parkinson’s disease drug used to relieve spasms in patients.
Mallinckrodt Plc agreed to buy Questcor Pharmaceuticals Inc. for $5.6 billion to add specialty drugs in the latest industry deal that moves a U.S. company to Ireland for a lower tax rate.
Mergers and acquisitions in the specialty pharmaceuticals industry just reached a new high.
This may be the year Valeant Pharmaceuticals International Inc. writes the check that vaults the serial acquirer into the top tier of drugmakers.
"If they want to stay independent, then going on a bit of a shopping spree makes it harder for another entity to go after them."
- David Amsellem on Jun 04, 2014